Rivaroxaban for the treatment of cerebral venous thrombosis
Open Access
- 15 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Neurology
- Vol. 21 (1), 1-6
- https://doi.org/10.1186/s12883-021-02091-1
Abstract
New Oral Anticoagulants (NOACs) such as Rivaroxaban are introduced as alternatives to conventional vitamin-K antagonists in the long-term treatment of thrombotic events due to their lower bleeding risk. There is a lack of evidence on the effectiveness and safety of Rivaroxaban in Cerebral venous thrombosis (CVT). This study aims to assess the effectiveness and bleeding risk of Rivaroxaban in comparison with Warfarin for the treatment of CVT. 36 patients with diagnosis of CVT were included. Clinical and background information was assessed on admission and patients were followed for at least 12 months. Measured outcomes were modified Rankin Scale (mRS), evidence of recanalization on contrast-enhanced Brain MR venography (MRV) and major or minor bleeding. Patients were divided into two groups according to the type of oral anticoagulant (Rivaroxaban vs Warfarin). Groups were compared in terms of final outcomes and side effects. Overall, 13 (36.11%) patients received Warfarin and 23 (63.89%) received Rivaroxaban. Optimal mRS score (0–1) was attained in 9 of 10 (90%) of patients treated with Rivaroxaban and 19 of 22 (86.36%) of patients received Warfarin. MRV showed complete or partial recanalization in 12 of 14 (85.71%) patients treated with Rivaroxaban and all patients in the Warfarin group. There was no significant difference between the two groups in terms of major and minor hemorrhage. Rivaroxaban holds promise for the treatment of CVT.This publication has 24 references indexed in Scilit:
- New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectivenessDrug Design, Development and Therapy, 2014
- Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studiesThrombosis Journal, 2013
- Rivaroxaban for the Treatment of Pulmonary EmbolismAdvances in Therapy, 2013
- Antithrombotic alternatives for stroke prevention in atrial fibrillation: critical differences and remaining questionsDrugs in Context, 2013
- Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary EmbolismThe New England Journal of Medicine, 2012
- Diagnosis and Management of Cerebral Venous ThrombosisStroke, 2011
- Oral Rivaroxaban for Symptomatic Venous ThromboembolismThe New England Journal of Medicine, 2010
- Cerebral venous thrombosis: an updateThe Lancet Neurology, 2007
- Clinical Impact of Bleeding in Patients Taking Oral Anticoagulant Therapy for Venous ThromboembolismAnnals of Internal Medicine, 2003
- Recombinant tissue plasminogen activator in acute thrombotic and embolic strokeAnnals of Neurology, 1992